Fernandez-Mateos, J.Seijas-Tamayo, R.Mesia, R.Taberna, M.Pastor Borgonon, M.Perez-Ruiz, E.Klain, J. C. AdansaVazquez Fernandez, S.del Barco Morillo, E.Lozano, A.Gonzalez Sarmiento, R.Cruz-Hernandez, J. J.Spanish Head Neck Canc Cooperative2025-01-072025-01-072016-12-011368-8375https://hdl.handle.net/10668/26658Objectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (penAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Head and neck squamous cell carcinoma (HNSCC)Epidermal growth factor receptor (EGFR)PolymorphismSNPEGFRCCDN1FCGR2AFCGR3AKRAS-LCS6CetuximabToxicityPlatinum-based chemotherapyPhase-iiPlus cetuximabSkin toxicitySingle-agentLung-cancerOpen-labelRiskEpidemiologyCombinationresearch article27938998open access10.1016/j.oraloncology.2016.10.0061879-0593https://doi.org/10.1016/j.oraloncology.2016.10.006392637300011